封面
市場調查報告書
商品編碼
2174857

基因技術市場:全球市場預測,2026-2032年

Gene Transfer Technologies Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,基因轉移技術市場規模將達到 105.1 億美元,複合年成長率為 14.09%。

主要市場統計數據
基準年 2025 41.7億美元
預計年份:2026年 47.6億美元
預測年份 2032 105.1億美元
複合年成長率 (%) 14.09%

基因轉移技術:概述

基因轉移技術能夠將遺傳物質引入、修飾或遞送至科研、生物技術、醫學和工業應用領域。該領域涵蓋病毒和非病毒載體、體外和體內方法、基因編輯工作流程以及旨在提高靶向性、表達水平、安全性和生產一致性的遞送系統。分子生物學、細胞工程、生物製程、監管科學和臨床應用等領域的進步推動了標靶化技術的發展。

技術和操作方面的變革,以重組基因轉移

該領域的研究格局正從概念驗證(PoC)實驗轉向更可控、更具應用針對性的平台。關鍵變化包括載體工程的改進、高純度核酸的生產、自動化細胞處理流程、增強的分析表徵,以及對重複給藥、免疫抗原性、組織標靶化和長期安全性的日益重視。非病毒遞送方法與病毒系統一樣,正日益成為重要的策略工具,尤其是在遞送物質的柔軟性、生產規模化或重複給藥至關重要的情況下。標準化的品管和更清晰的可比性策略在研發和商業化準備階段也發揮核心作用。

人工智慧正在加速設計、最佳化和品管。

人工智慧應用於基因轉移工作流程的整體,包括序列和載體設計、組織親和性預測、啟動子和調控元件最佳化、遞送效率分析以及潛在安全風險識別。機器學習工具可以透過整合基因組、轉錄組、結構和過程資料來幫助確定實驗的優先順序。在生產製造中,人工智慧驅動的監控可以提高偏差檢測的準確性,並實現更一致的製程控制。然而,模型的可靠性取決於具有代表性的資料集、透明的檢驗、安全的資料管治以及實驗支援。因此,人工智慧並非生物學和監管證據的替代品,而是為其提供基礎。

區域洞察:監管和生產重點的多樣性

北美擁有強大的生物醫學研究能力和先進的臨床開發及生產生態系統,監管審查著重於安全性、有效性、持久性和產品一致性的證據。歐洲優先考慮的是協調一致的法規、品質系統、倫理監管和跨境研究,歐盟支持科學和轉化框架的協調。亞太地區的特點是生物製造能力不斷增強、研究活躍且監管途徑多樣化,日本、中國、韓國、印度和澳洲各自發揮獨特的優勢。拉丁美洲正在推動基因治療和先進生技藥品的能力建設,同時注重可及性、專業基礎設施和技術轉移。中東正在投資研究能力、精準醫療和醫療保健現代化。同時,非洲的優先事項包括與當地實際情況相關的研究、人力資源發展、具有韌性的實驗室基礎設施和公平的醫療服務取得。

團隊洞察:協作塑造能力與管治

東協成員國在生物技術新興能力、醫療保健需求和監管成熟度方面存在差異,因此區域合作和通用標準尤其重要。金磚國家擁有龐大的研發、製造和醫療保健體系,但政策環境各不相同,這既為合作創造了機遇,也帶來了技術轉移和品質標準協調方面的複雜要求。歐盟受益於監管協調和跨境科學網路。七國集團(G7)在尖端研究、臨床應用、標準制定和生物製造方面做出了重大貢獻。海灣合作理事會(GCC)成員國正在加強對精準醫療、醫療保健基礎設施和國家生物技術能力的投資。北約成員國擁有廣泛的科學和工業能力,在生物安全、供應鏈韌性和負責任創新方面的合作仍然至關重要。

國家概況:主要國內市場的獨特優勢

美國在學術研究、臨床研究、投資和製造領域擁有雄厚的實力,並有完善的法律規範來支持。加拿大在生物醫學研究、細胞處理和公共部門科學領域表現卓越。英國在基因組學、臨床研究和轉化醫學方面擁有傑出的專業知識。法國、德國、義大利和西班牙透過歐洲研究網路、專科醫院、生物製造和監管協調做出貢獻。中國在研發、製造和臨床開發方面擁有相當的實力,而日本則專注於先進的再生醫學、品管系統和臨床應用。韓國正在建立強大的生物技術和製造能力。印度正在拓展其研發、藥品生產和成本效益高的開發模式。澳洲支持臨床研究、生物技術創新和專業製造。巴西和墨西哥正致力於加強區域能力、基礎設施和存取管道。俄羅斯擁有科學和工業的專業知識,但在國際合作、供應鏈和監管協調方面面臨許多限制。

產業領導者的策略重點

產業領導者應根據​​目標機構、有效載荷、給藥途徑、給藥策略和證據要求來選擇平台,而不是將病毒載體和非病毒載體系統視為可互換。他們還應儘早建立品質源於設計 (QbD) 計劃,包括對鑑定、效力、純度、載體特性、殘留和產品一致性檢驗的檢測。投資於模組化生產、熟練人員、安全供應鏈和可擴展的分析能力可以減少開發阻力。各機構應在有據可查的驗證、人工監督和健全的資料管治下,選擇性地利用人工智慧。與醫院、學術機構、合約開發商和監管機構夥伴關係可以提高轉化相關性。最後,除了技術表現之外,領導者還應關注可負擔性、患者選擇、長期追蹤、生物安全和公平獲取。

調查方法執行摘要

本概要對基因轉移技術的現狀進行了結構化的定性回顧,重點關注技術進步、配套工具、區域背景、經濟和製度格局以及部分國家的能力。內容整合了已建立的科學和監管主題,包括載體工程、核酸遞送、細胞處理、生物製造、安全性評估、臨床應用和數據驅動開發。區域比較考慮了研究基礎設施、監管合作、生產準備、醫療保健系統、勞動力和可及性。本分析有意排除了市場規模估算和預測、市場佔有率、預測以及公司特定評估;因此,在進行投資和營運決策時,應結合最新的主要監管、臨床和技術審查結果來使用本分析。

結論:建構更安全、更具適應性的基因轉移平台。

基因轉移技術正透過遞送科學、基因編輯、細胞工程、分析、製造和計算技術的融合而不斷發展。這項進展不僅取決於生物學性能的提升,還取決於可重複的品質、永續的安全性、可製造性以及有意義的臨床或工業效用。鑑於區域和國家能力持續存在差異,合作、人才培養、基礎設施投資和統一標準的建立至關重要。那些將技術創新與嚴格檢驗、負責任的人工智慧應用、穩健的營運和公平的獲取途徑相結合的機構,將更有能力將基因轉移技術的進步轉化為可靠的應用。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章 基因轉殖技術市場:依技術分類

  • 非病毒基因轉移
    • 電穿孔
    • 基於脂質的轉染
    • 基於聚合物的遞送
  • 病毒介導的基因轉移
    • 腺結合病毒
    • 腺病毒
    • 慢病毒
    • 逆轉錄病毒

第8章:基因轉殖技術市場:依應用領域分類

  • 基因治療
  • 個人化醫療
  • 再生醫學
  • 疫苗研發

第9章:基因轉殖技術市場:依治療領域分類

  • 心血管疾病
  • 感染疾病
  • 代謝性疾病
  • 肌肉骨骼疾病
  • 神經病變
  • 腫瘤學(癌症)

第10章 基因轉殖技術市場:依最終用戶細分

  • 學術研究機構
  • 生物製藥公司
  • 受託研究機構

第11章 基因轉殖技術市場:依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 基因轉殖技術市場:依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 基因技術市場:依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第15章:公司簡介

  • 4D Molecular Therapeutics, Inc.
  • Beam Therapeutics Inc.
  • Bio-Rad Laboratories, Inc.
  • Bluebird Bio, Inc.
  • Cellectis SA
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd
  • Generation Bio Co.
  • Genethon
  • Genprex, Inc.
  • Horizon Therapeutics plc by Amgen Inc
  • Intellia Therapeutics, Inc.
  • Lonza Group AG
  • MeiraGTx Holdings plc
  • Merck KGaA
  • Moderna, Inc.
  • Novartis AG
  • Orchard Therapeutics plc
  • Oxford Biomedica plc
  • Pfizer Inc.
  • Precision BioSciences, Inc.
  • Sangamo Therapeutics, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

第16章 主要專家

Product Code: MRR-50750BF5CB82

The Gene Transfer Technologies Market is projected to grow by USD 10.51 billion at a CAGR of 14.09% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.17 billion
Estimated Year [2026] USD 4.76 billion
Forecast Year [2032] USD 10.51 billion
CAGR (%) 14.09%

Gene Transfer Technologies: Executive Overview

Gene transfer technologies enable the introduction, modification, or delivery of genetic material in research, biotechnology, medicine, and industrial applications. The field spans viral and nonviral vectors, ex vivo and in vivo approaches, gene-editing workflows, and delivery systems designed to improve targeting, expression, safety, and manufacturing consistency. Its development is shaped by advances in molecular biology, cell engineering, bioprocessing, regulatory science, and clinical translation.

Technological and Operational Shifts Reshaping Gene Transfer

The landscape is moving from proof-of-concept experimentation toward more controlled, application-specific platforms. Important shifts include improved vector engineering, higher-purity nucleic-acid production, automated cell-processing workflows, better analytical characterization, and increased attention to repeat dosing, immunogenicity, tissue targeting, and long-term safety. Nonviral delivery is gaining strategic relevance alongside viral systems, particularly where payload flexibility, manufacturing scalability, or redosing are important. Standardized quality controls and clearer comparability strategies are also becoming central to development and commercialization readiness.

Artificial Intelligence Is Accelerating Design, Optimization, and Quality Control

Artificial intelligence is being applied across the gene-transfer workflow, including sequence and vector design, prediction of tissue tropism, optimization of promoters and regulatory elements, analysis of delivery efficiency, and identification of potential safety liabilities. Machine-learning tools can help prioritize experiments by integrating genomic, transcriptomic, structural, and process data. In manufacturing, AI-supported monitoring may improve detection of deviations and support more consistent process control. However, model reliability depends on representative datasets, transparent validation, secure data governance, and experimental confirmation; AI is therefore an enabling layer rather than a substitute for biological and regulatory evidence.

Regional Insights: Diverse Regulatory and Manufacturing Priorities

North America combines strong biomedical research capacity with advanced clinical-development and manufacturing ecosystems, while regulatory scrutiny emphasizes evidence of safety, potency, durability, and product consistency. Europe places substantial weight on harmonized regulation, quality systems, ethical oversight, and cross-border research, with the European Union supporting collaborative scientific and translational frameworks. Asia-Pacific is characterized by expanding biomanufacturing capabilities, substantial research activity, and varied regulatory pathways, with Japan, China, South Korea, India, and Australia each contributing distinct strengths. Latin America is developing gene-therapy and advanced-biologics capabilities while focusing on access, specialized infrastructure, and technology transfer. The Middle East is investing in research capacity, precision medicine, and healthcare modernization, whereas Africa's priorities include locally relevant research, workforce development, resilient laboratory infrastructure, and equitable access.

Group Insights: Cooperation Shapes Capability and Governance

ASEAN members present a varied combination of emerging biotechnology capacity, healthcare needs, and regulatory maturity, making regional coordination and shared standards particularly valuable. BRICS countries encompass major research, manufacturing, and healthcare systems with different policy environments, creating opportunities for collaboration alongside complex requirements for technology transfer and quality alignment. The European Union benefits from regulatory coordination and cross-border scientific networks. G7 economies provide significant contributions to advanced research, clinical translation, standards development, and biomanufacturing. GCC countries are strengthening investment in precision medicine, healthcare infrastructure, and national biotechnology capabilities. NATO members bring extensive scientific and industrial capacity, while cooperation on biosecurity, supply resilience, and responsible innovation remains important.

Country Insights: Distinct Strengths Across Key National Markets

The United States combines deep academic, clinical, investment, and manufacturing capabilities, supported by an established regulatory framework. Canada contributes strengths in biomedical research, cell processing, and public-sector science. The United Kingdom has notable expertise in genomics, clinical research, and translational medicine. France, Germany, Italy, and Spain contribute through European research networks, specialized hospitals, biomanufacturing, and regulatory coordination. China has substantial research, manufacturing, and clinical-development capabilities, while Japan emphasizes advanced regenerative medicine, quality systems, and clinical translation. South Korea is building strong biotechnology and manufacturing capacity. India is expanding research, pharmaceutical production, and cost-sensitive development models. Australia supports clinical research, biotechnology innovation, and specialized manufacturing. Brazil and Mexico are strengthening regional capabilities, infrastructure, and access pathways. Russia retains scientific and industrial expertise but faces constraints related to international collaboration, supply chains, and regulatory connectivity.

Strategic Priorities for Industry Leaders

Industry leaders should align platform selection with the intended tissue, payload, route of administration, dosing strategy, and evidence requirements rather than treating viral and nonviral systems as interchangeable. They should establish quality-by-design programs early, including validated assays for identity, potency, purity, vector attributes, residuals, and product consistency. Investment in modular manufacturing, skilled personnel, secure supply chains, and scalable analytical capacity can reduce development friction. Organizations should use AI selectively with documented validation, human oversight, and robust data governance. Partnerships with hospitals, academic groups, contract developers, and regulators can improve translational relevance. Finally, leaders should address affordability, patient selection, long-term follow-up, biosecurity, and equitable access alongside technical performance.

Research Methodology for the Executive Summary

This summary uses a structured qualitative review of the gene transfer technology landscape, organized around technology evolution, enabling tools, regional conditions, economic and institutional groupings, and selected national capabilities. Insights are synthesized from established scientific and regulatory themes, including vector engineering, nucleic-acid delivery, cell processing, biomanufacturing, safety assessment, clinical translation, and data-enabled development. Geographic comparisons consider research infrastructure, regulatory coordination, manufacturing readiness, healthcare capacity, workforce, and access considerations. The analysis intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific assessments, and should be complemented by current primary-source regulatory, clinical, and technical review for investment or operational decisions.

Conclusion: Building Safer, More Adaptable Gene Transfer Platforms

Gene transfer technologies are advancing through the convergence of delivery science, gene editing, cell engineering, analytics, manufacturing, and computational methods. Progress will depend not only on improving biological performance but also on demonstrating reproducible quality, durable safety, manufacturability, and meaningful clinical or industrial utility. Regional and national capabilities remain uneven, making collaboration, workforce development, infrastructure investment, and harmonized standards important priorities. Organizations that integrate technical innovation with disciplined validation, responsible AI use, resilient operations, and equitable access will be better positioned to translate gene transfer advances into dependable applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gene Transfer Technologies Market, by Technology

  • 7.1. Introduction
  • 7.2. Non-Viral Gene Delivery
    • 7.2.1. Electroporation
    • 7.2.2. Lipid-Based Transfection
    • 7.2.3. Polymer-Based Delivery
  • 7.3. Viral Gene Delivery
    • 7.3.1. Adeno-Associated Virus
    • 7.3.2. Adenovirus
    • 7.3.3. Lentivirus
    • 7.3.4. Retrovirus

8. Gene Transfer Technologies Market, by Applications

  • 8.1. Introduction
  • 8.2. Gene Therapy
  • 8.3. Personalized Medicine
  • 8.4. Regenerative Medicine
  • 8.5. Vaccines Development

9. Gene Transfer Technologies Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Infectious Diseases
  • 9.4. Metabolic Disorders
  • 9.5. Musculoskeletal Disorders
  • 9.6. Neurological Disorders
  • 9.7. Oncology (Cancer)

10. Gene Transfer Technologies Market, by End User Segments

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Biopharmaceutical Companies
  • 10.4. Contract Research Organizations

11. Gene Transfer Technologies Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. Gene Transfer Technologies Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. Gene Transfer Technologies Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. 4D Molecular Therapeutics, Inc.
  • 15.2. Beam Therapeutics Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. Bluebird Bio, Inc.
  • 15.5. Cellectis S.A.
  • 15.6. Editas Medicine, Inc.
  • 15.7. F. Hoffmann-La Roche Ltd
  • 15.8. Generation Bio Co.
  • 15.9. Genethon
  • 15.10. Genprex, Inc.
  • 15.11. Horizon Therapeutics plc by Amgen Inc
  • 15.12. Intellia Therapeutics, Inc.
  • 15.13. Lonza Group AG
  • 15.14. MeiraGTx Holdings plc
  • 15.15. Merck KGaA
  • 15.16. Moderna, Inc.
  • 15.17. Novartis AG
  • 15.18. Orchard Therapeutics plc
  • 15.19. Oxford Biomedica plc
  • 15.20. Pfizer Inc.
  • 15.21. Precision BioSciences, Inc.
  • 15.22. Sangamo Therapeutics, Inc.
  • 15.23. Takara Bio Inc.
  • 15.24. Thermo Fisher Scientific Inc.

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Gene Transfer Technologies Market, Years Considered for the Study
  • FIGURE 2. Global Gene Transfer Technologies Market, Research Design
  • FIGURE 3. Global Gene Transfer Technologies Market, Research Framework
  • FIGURE 4. Global Gene Transfer Technologies Market, Data Triangulation
  • FIGURE 5. Global Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Gene Transfer Technologies Market Size, by Technology, 2025 vs 2032 (%)
  • FIGURE 7. Global Gene Transfer Technologies Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Gene Transfer Technologies Market Size, by Applications, 2025 vs 2032 (%)
  • FIGURE 9. Global Gene Transfer Technologies Market Size, by Applications, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Gene Transfer Technologies Market Size, by Therapeutic Area, 2025 vs 2032 (%)
  • FIGURE 11. Global Gene Transfer Technologies Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Gene Transfer Technologies Market Size, by End User Segments, 2025 vs 2032 (%)
  • FIGURE 13. Global Gene Transfer Technologies Market Size, by End User Segments, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Gene Transfer Technologies Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Gene Transfer Technologies Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Gene Transfer Technologies Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Gene Transfer Technologies Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Gene Transfer Technologies Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Gene Transfer Technologies Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Gene Transfer Technologies Market Segmentation & Coverage
  • TABLE 2. Global Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 4. Global Non-Viral Gene Delivery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Non-Viral Gene Delivery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Non-Viral Gene Delivery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Electroporation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Electroporation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Electroporation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Lipid-Based Transfection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Lipid-Based Transfection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Lipid-Based Transfection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Polymer-Based Delivery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Polymer-Based Delivery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Polymer-Based Delivery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Viral Gene Delivery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Viral Gene Delivery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Viral Gene Delivery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Adeno-Associated Virus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Adeno-Associated Virus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Adeno-Associated Virus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Adenovirus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Adenovirus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Adenovirus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Lentivirus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Lentivirus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Lentivirus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Retrovirus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Retrovirus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Retrovirus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 32. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Personalized Medicine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Personalized Medicine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Personalized Medicine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Regenerative Medicine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Regenerative Medicine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Regenerative Medicine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Vaccines Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Vaccines Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Vaccines Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 45. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Musculoskeletal Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Global Musculoskeletal Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 56. Global Musculoskeletal Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 57. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Oncology (Cancer) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Oncology (Cancer) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Oncology (Cancer) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 64. Global Academic & Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Academic & Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Academic & Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Biopharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Biopharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Biopharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Gene Transfer Technologies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Asia-Pacific Gene Transfer Technologies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Asia-Pacific Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 76. Asia-Pacific Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 77. Asia-Pacific Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 78. Asia-Pacific Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 79. Asia-Pacific Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 80. Asia-Pacific Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 81. North America Gene Transfer Technologies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. North America Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 83. North America Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 84. North America Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 85. North America Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 86. North America Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 87. North America Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 88. Latin America Gene Transfer Technologies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Latin America Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 90. Latin America Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 91. Latin America Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 92. Latin America Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 93. Latin America Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 94. Latin America Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 95. Europe Gene Transfer Technologies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Europe Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 97. Europe Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 98. Europe Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 99. Europe Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 100. Europe Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 101. Europe Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 102. Middle East Gene Transfer Technologies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 103. Middle East Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 104. Middle East Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 105. Middle East Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 106. Middle East Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 107. Middle East Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 108. Middle East Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 109. Africa Gene Transfer Technologies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 110. Africa Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 111. Africa Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 112. Africa Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 113. Africa Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 114. Africa Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 115. Africa Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 116. Global Gene Transfer Technologies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 117. ASEAN Gene Transfer Technologies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 118. ASEAN Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 119. ASEAN Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 120. ASEAN Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 121. ASEAN Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 122. ASEAN Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 123. ASEAN Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 124. GCC Gene Transfer Technologies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. GCC Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 126. GCC Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 127. GCC Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 128. GCC Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 129. GCC Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 130. GCC Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 131. European Union Gene Transfer Technologies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 132. European Union Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 133. European Union Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 134. European Union Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 135. European Union Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 136. European Union Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 137. European Union Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 138. BRICS Gene Transfer Technologies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 139. BRICS Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 140. BRICS Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 141. BRICS Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 142. BRICS Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 143. BRICS Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 144. BRICS Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 145. G7 Gene Transfer Technologies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 146. G7 Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 147. G7 Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 148. G7 Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 149. G7 Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 150. G7 Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 151. G7 Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 152. NATO Gene Transfer Technologies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 153. NATO Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 154. NATO Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 155. NATO Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 156. NATO Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 157. NATO Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 158. NATO Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 159. Global Gene Transfer Technologies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 160. United States Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 161. United States Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 162. United States Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 163. United States Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 164. United States Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 165. United States Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 166. United States Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 167. Canada Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 168. Canada Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 169. Canada Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 170. Canada Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 171. Canada Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 172. Canada Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 173. Canada Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 174. Mexico Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 175. Mexico Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 176. Mexico Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 177. Mexico Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 178. Mexico Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 179. Mexico Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 180. Mexico Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 181. Brazil Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 182. Brazil Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 183. Brazil Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 184. Brazil Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 185. Brazil Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 186. Brazil Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 187. Brazil Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 188. United Kingdom Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 189. United Kingdom Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 190. United Kingdom Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 191. United Kingdom Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 192. United Kingdom Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 193. United Kingdom Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 194. United Kingdom Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 195. Germany Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 196. Germany Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 197. Germany Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 198. Germany Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 199. Germany Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 200. Germany Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 201. Germany Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 202. France Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 203. France Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 204. France Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 205. France Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 206. France Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 207. France Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 208. France Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 209. Russia Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 210. Russia Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 211. Russia Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 212. Russia Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 213. Russia Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 214. Russia Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 215. Russia Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 216. Italy Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 217. Italy Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 218. Italy Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 219. Italy Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 220. Italy Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 221. Italy Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 222. Italy Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 223. Spain Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 224. Spain Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 225. Spain Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 226. Spain Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 227. Spain Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 228. Spain Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 229. Spain Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 230. China Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 231. China Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 232. China Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 233. China Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 234. China Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 235. China Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 236. China Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 237. India Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 238. India Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 239. India Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 240. India Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 241. India Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 242. India Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 243. India Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 244. Japan Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 245. Japan Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 246. Japan Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 247. Japan Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 248. Japan Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 249. Japan Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 250. Japan Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 251. Australia Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 252. Australia Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 253. Australia Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 254. Australia Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 255. Australia Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 256. Australia Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 257. Australia Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 258. South Korea Gene Transfer Technologies Market Size, 2017-2032 (USD Million)
  • TABLE 259. South Korea Gene Transfer Technologies Market Size, by Technology, 2017-2032 (USD Million)
  • TABLE 260. South Korea Gene Transfer Technologies Market Size, by Non-Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 261. South Korea Gene Transfer Technologies Market Size, by Viral Gene Delivery, 2017-2032 (USD Million)
  • TABLE 262. South Korea Gene Transfer Technologies Market Size, by Applications, 2017-2032 (USD Million)
  • TABLE 263. South Korea Gene Transfer Technologies Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 264. South Korea Gene Transfer Technologies Market Size, by End User Segments, 2017-2032 (USD Million)
  • TABLE 265. Global Gene Transfer Technologies Market Share, by Key Player, 2025
  • TABLE 266. Global Gene Transfer Technologies Market, Key Experts